Department of Obstetrics and Gynecological Sciences, University of Messina, Messina, Italy.
Climacteric. 2012 Oct;15(5):490-5. doi: 10.3109/13697137.2011.631063. Epub 2011 Dec 23.
To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome.
Eighty outpatient postmenopausal women, affected by metabolic syndrome, were enrolled in a 12-month study. All women were treated with a low-energy diet, and then they were randomly assigned to myo-inositol 2 g b.i.d. (n = 40) or placebo (n = 40). All the women were evaluated for serum glucose, insulin, HOMA-IR (Homeostasis Model Assessment-Insulin Resistance), triglycerides, total and high density lipoprotein cholesterol, body mass index (BMI), waist circumference and blood pressure at baseline and after 12 months of treatment.
With the exception of BMI and waist circumference, after 12 months of treatment, all the parameters studied showed a significant improvement in the myo-inositol group compared to the control group. At the end of the study, in the myo-inositol group, the number of women without metabolic syndrome was eight (20%) whereas, in the control group, only one woman no longer had the metabolic syndrome after 12 months of diet.
Myo-inositol might be considered one of the insulin-sensitizing substances in the treatment of metabolic syndrome.
评估肌醇治疗对患有代谢综合征的女性某些生化参数的 12 个月影响。
80 名患有代谢综合征的门诊绝经后妇女参加了一项为期 12 个月的研究。所有妇女均接受低热量饮食治疗，然后随机分为肌醇 2 g 每日两次（n = 40）或安慰剂组（n = 40）。所有妇女均在基线和治疗 12 个月后评估血清葡萄糖、胰岛素、HOMA-IR（胰岛素抵抗的稳态模型评估）、甘油三酯、总胆固醇和高密度脂蛋白胆固醇、体重指数（BMI）、腰围和血压。
除 BMI 和腰围外，与对照组相比，肌醇组在治疗 12 个月后所有研究参数均显著改善。在研究结束时，在肌醇组中，有 8 名（20%）妇女没有代谢综合征，而在对照组中，只有 1 名妇女在接受 12 个月饮食治疗后不再患有代谢综合征。
肌醇可能被认为是治疗代谢综合征的胰岛素增敏物质之一。
